ZPI Inhibiting Nucleic Acid Duplexes With Terminal Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid compounds for therapeutic use, such as siRNA, face challenges in effectively inhibiting specific gene expression, particularly for the ZPI gene, which is involved in various diseases and conditions.
Innovation Solution
Development of novel nucleic acid compounds with specific duplex regions comprising first and second strands that are at least partially complementary to the ZPI gene RNA, with sequences differing by 0 or 1 nucleosides from listed sequences, to inhibit ZPI expression effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small organic compounds are used to inhibit protein function, then the mechanism is simple, but the specificity and efficacy for gene silencing is insufficient
Solution Approach 1:
The nucleic acid compound is divided into distinct functional segments: a duplex region (17-30 nucleotides) for target recognition and binding, and terminal regions (5-10 nucleotides each) that may contain modifications for stability and activity. This segmentation allows optimization of each region's function independently, achieving high specificity through the duplex region while managing complexity through standardized terminal structures.
Solution Approach 2:
Different regions of the nucleic acid compound have specialized properties: the duplex region is designed for complementary base pairing with the ZPI gene RNA target to ensure specificity, while the terminal regions may contain chemical modifications (such as 2'-O-methyl, phosphorothioate) to enhance stability and resistance to nucleases. This local differentiation of properties allows the compound to achieve both high target specificity and improved pharmacological properties.
2Productivity
If nucleic acid compounds with high complementarity to ZPI RNA are designed, then gene silencing efficacy is improved, but off-target effects and immunogenicity may increase
Solution Approach 1:
The duplex region is designed with 17-30 nucleotides of complementarity, which is sufficient for effective gene silencing but not excessively long to cause off-target binding. This optimized length provides strong enough binding to achieve high efficacy while avoiding the accumulation of multiple weak off-target interactions that would occur with longer sequences. The partial complementarity (allowing 1-4 mismatches) further refines specificity by requiring sufficient match quality without demanding perfect complementarity.
Solution Approach 2:
Chemical modifications at the terminal regions (such as 2'-O-methyl, phosphorothioate linkages) change the physical and chemical parameters of the nucleic acid compound without affecting the central duplex region's ability to bind the target. These parameter changes enhance stability against degradation and reduce immunogenicity while maintaining the gene silencing efficacy provided by the complementary duplex region.
3Duration of action of stationary object
If modified nucleosides are incorporated to enhance stability, then compound half-life is improved, but manufacturing complexity increases
Solution Approach 1:
Chemical modifications are applied locally at the terminal regions (5-10 nucleotides from each end) rather than throughout the entire sequence. This localized modification strategy provides the stability benefits of modified nucleosides (such as 2'-O-methyl and phosphorothioate) while limiting the manufacturing complexity to only portions of the molecule. The central duplex region typically uses standard nucleotides, simplifying synthesis while maintaining high target affinity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described nucleic acid compounds demonstrate the ability to specifically inhibit ZPI gene expression, offering potential therapeutic benefits for treating diseases related to ZPI, with improved specificity and efficacy compared to existing technologies.
Implementation Method 1
a duplex region that comprises a first strand and a second strand that is at least partially complementary to the first strand, wherein said first strand is: (i) at least partially complementary to a portion of RNA transcribed from the ZPI gene
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides novel nucleic acid compound suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.